BioSpace News Archive

Biodexa Pharmaceuticals PLC announces that its Notice of Annual General Meeting was posted to shareholders yesterday, along with the Annual Report for the year ended 31 December 2023.

AlzeCure Pharma AB announced that Professor Jan Lundberg has been elected as a new board member at the company’s annual general meeting in 2024.

Ocugen, Inc. announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST —a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life.

Merck, known as MSD outside of the United States and Canada, announced that new data for four approved oncology medicines and four pipeline candidates in more than 25 types of cancer will be presented at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago from May 31-June 4.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on respiratory genetic medicine candidates KB407 and KB408 at the American Thoracic Society (ATS) 2024 International Conference being held from May 17-22, 2024 in San Diego, California.

The company behind the hormone-free contraceptive Phexxi®, Evofem Biosciences, Inc. announced financial results for the first quarter of 2024.

Bio-Path Holdings, Inc. announced its financial results for the first quarter ended March 31, 2024 and provided an update on recent corporate developments.

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Olema Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib for the treatment of ER+/HER2- metastatic breast cancer.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today provided an update from the Company’s ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant rejection.